Agenda

Agenda

CME accreditation badge

This program has been accredited for 1.5 hours of CME credit.

  • 2026-06-22 19:00 UTC
    Gilles Salles

    Welcome and introductions 

  • 2026-06-22 19:10 UTC
    Susan O’Brien

    BTK inhibitors in chronic lymphocytic leukemia: Mechanisms, clinical considerations, and unmet needs 

  • 2026-06-22 19:30 UTC
    Farrukh Awan

    BTK inhibitors in practice: Treatment selection and emerging clinical evidence 

  • 2026-06-22 19:55 UTC
    Francesc Bosch

    Optimizing chronic lymphocytic leukemia management in a changing landscape 

  • 2026-06-22 20:15 UTC
    Gilles Salles ,  Susan O’Brien ,  Farrukh Awan ,  Francesc Bosch

    Q&A session

  • 2026-06-22 20:25 UTC
    Gilles Salles

    Closing remarks and EBAC symposium evaluation

Learning objectives

Following the symposium, learners will be able to: 

  • Describe clinically relevant differences between BTK inhibitors, including covalent and non-covalent binding and selectivity, and their implications for treatment of CLL.
  • Recall key clinical data supporting BTK inhibitor-based treatment strategies for first-line and relapsed/refractory CLL.
  • Apply evidence-based considerations for selecting BTK inhibitor-based treatment strategies for patients with CLL, considering prior therapies, disease and molecular risk features, resistance mutations, comorbidities, and patient-related factors.
  • Discuss the role of BTK inhibitors within evolving treatment paradigms for CLL.

Registration form

Registration is free.

Required fields

Thank you!

You have successfully registered for the webinar.

Please check your email for further information on how to attend.

Add to Calendar